Skip to main content
Top
Published in: Supportive Care in Cancer 5/2013

01-05-2013 | Letter to the Editor

Can a phone call be more effective than an intrathecal implanted pump?

Authors: Sebastiano Mercadante, Patrizia Giardina

Published in: Supportive Care in Cancer | Issue 5/2013

Login to get access

Excerpt

Pain is one of the most prevalent, burdensome, and feared symptoms among cancer patients. Even when the basic principles for the use of analgesic drugs are adhered to, some patients experience insufficient pain relief or considerable adverse effects from systemic opioids. Opioid switching or even change of the route of opioid administration may improve the opioid response in most cases, and only a small proportion of patients with cancer pain should be candidates for spinal treatment. A spinal treatment is indicated if systemic treatment has failed, either because of inadequate analgesia or because of intolerable side effects [10]. Although the proportion of cancer patients who may benefit from invasive therapies is small, it is still extremely important, given the level of suffering of patients unresponsive to multiple trials of opioids, possibly receiving high doses of opioids unsuccessfully and having consistent adverse effects. However, the real need for spinal analgesia remains unknown, as the size of the group from which patients are selected for spinal analgesia is rarely reported, and spinal opioids are often started before systemic opioid administration is optimized [11]. According to the prevalent and more accepted opinion in the field of cancer pain, indications for the use of spinal opioids should include patients treated by systemic opioids with effective pain relief but with unacceptable side effects, or unsuccessful treatment with sequential strong opioid drug trials despite escalating doses [11]. …
Literature
1.
go back to reference Brogan SE, Winter NB (2011) Patient-controlled intrathecal analgesia for the management of breakthrough cancer pain: a retrospective review and commentary. Pain Med 12:1758–1768PubMedCrossRef Brogan SE, Winter NB (2011) Patient-controlled intrathecal analgesia for the management of breakthrough cancer pain: a retrospective review and commentary. Pain Med 12:1758–1768PubMedCrossRef
2.
3.
go back to reference Deer T, Smith H, Burton A et al (2011) Comprehensive consensus based guidelines on intrathecal drug delivery systems in the treatment of pain caused by cancer pain. Pain Phys 14:E283–E312 Deer T, Smith H, Burton A et al (2011) Comprehensive consensus based guidelines on intrathecal drug delivery systems in the treatment of pain caused by cancer pain. Pain Phys 14:E283–E312
4.
go back to reference Mercadante S, Agnello A, Armata MG, Pumo S (1997) The inappropriate use of the epidural route in cancer pain. J Pain Symptom Manage 13:233–237PubMedCrossRef Mercadante S, Agnello A, Armata MG, Pumo S (1997) The inappropriate use of the epidural route in cancer pain. J Pain Symptom Manage 13:233–237PubMedCrossRef
5.
go back to reference Kalso E, Heiskanen T, Rantio M, Rosenberg PH, Vainio A (1996) Epidural and subcutaneous morphine in the management of cancer pain: a double-blind cross-over study. Pain 67:443–449PubMedCrossRef Kalso E, Heiskanen T, Rantio M, Rosenberg PH, Vainio A (1996) Epidural and subcutaneous morphine in the management of cancer pain: a double-blind cross-over study. Pain 67:443–449PubMedCrossRef
6.
go back to reference Mao JR, Price DD, Mayer DJ (1995) Mechanisms of hyperalgesia and morphine tolerance: a current view of their possible interactions. Pain 62:259–274PubMedCrossRef Mao JR, Price DD, Mayer DJ (1995) Mechanisms of hyperalgesia and morphine tolerance: a current view of their possible interactions. Pain 62:259–274PubMedCrossRef
7.
go back to reference Mercadante S (2004) Re: Rauck et al. Long-term intrathecal opioid therapy with a patient-activated, implanted delivery system for the treatment of refractory cancer pain. J Pain 5:138–139PubMedCrossRef Mercadante S (2004) Re: Rauck et al. Long-term intrathecal opioid therapy with a patient-activated, implanted delivery system for the treatment of refractory cancer pain. J Pain 5:138–139PubMedCrossRef
8.
go back to reference Mercadante S, Arcuri E, Ferrera P, Villari P, Mangione S (2005) Alternative treatments of breakthrough pain in patients receiving spinal analgesics for cancer pain. J Pain Symptom Manage 30:485–491PubMedCrossRef Mercadante S, Arcuri E, Ferrera P, Villari P, Mangione S (2005) Alternative treatments of breakthrough pain in patients receiving spinal analgesics for cancer pain. J Pain Symptom Manage 30:485–491PubMedCrossRef
9.
go back to reference Mercadante S, Ferrera P, Villari P, Arcuri E (2005) Local anesthetics for breakthrough pain in patients receiving intrathecal treatment for cancer pain management. Anesth Analg 100:1540PubMedCrossRef Mercadante S, Ferrera P, Villari P, Arcuri E (2005) Local anesthetics for breakthrough pain in patients receiving intrathecal treatment for cancer pain management. Anesth Analg 100:1540PubMedCrossRef
10.
go back to reference Mercadante S, Intravaia G, Villari P, Ferrera P, Riina S, David F, Mangione S (2007) Intrathecal treatment in cancer patients unresponsive to multiple trials of systemic opioids. Clin J Pain 23:793–798PubMedCrossRef Mercadante S, Intravaia G, Villari P, Ferrera P, Riina S, David F, Mangione S (2007) Intrathecal treatment in cancer patients unresponsive to multiple trials of systemic opioids. Clin J Pain 23:793–798PubMedCrossRef
11.
go back to reference Mercadante S, Porzio G, Gebbia V (2012) Spinal analgesia for advanced cancer patients: an update. Crit Rev Oncol Hematol 82:227–232PubMedCrossRef Mercadante S, Porzio G, Gebbia V (2012) Spinal analgesia for advanced cancer patients: an update. Crit Rev Oncol Hematol 82:227–232PubMedCrossRef
12.
go back to reference Rauck R, Cherry D, Boyer M, Kosek P, Dunn J, Alo K (2003) Long-term intrathecal opioid therapy with a patient-activated implanted delivery system for the treatment of refractory cancer pain. J Pain 4:441–447PubMedCrossRef Rauck R, Cherry D, Boyer M, Kosek P, Dunn J, Alo K (2003) Long-term intrathecal opioid therapy with a patient-activated implanted delivery system for the treatment of refractory cancer pain. J Pain 4:441–447PubMedCrossRef
13.
go back to reference Reddy A, Hui D, Bruera E (2012) A successful palliative care intervention for cancer pain refractory to intrathecal analgesia. J Pain Symptom Manage 44(1):124–130PubMedCrossRef Reddy A, Hui D, Bruera E (2012) A successful palliative care intervention for cancer pain refractory to intrathecal analgesia. J Pain Symptom Manage 44(1):124–130PubMedCrossRef
14.
go back to reference Smith TJ, Staats PS, Deer T et al (2002) Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management of refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol 20:4040–4049PubMedCrossRef Smith TJ, Staats PS, Deer T et al (2002) Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management of refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol 20:4040–4049PubMedCrossRef
15.
go back to reference Yennurajalingam S, Dev R, Walker PW, Reddy SK, Bruera E (2010) Challenges associated with spinal opioid therapy for pain in patients with advanced cancer: a report of three cases. J Pain Symptom Manage 39:930–935PubMedCrossRef Yennurajalingam S, Dev R, Walker PW, Reddy SK, Bruera E (2010) Challenges associated with spinal opioid therapy for pain in patients with advanced cancer: a report of three cases. J Pain Symptom Manage 39:930–935PubMedCrossRef
Metadata
Title
Can a phone call be more effective than an intrathecal implanted pump?
Authors
Sebastiano Mercadante
Patrizia Giardina
Publication date
01-05-2013
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 5/2013
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-012-1665-7

Other articles of this Issue 5/2013

Supportive Care in Cancer 5/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine